Declines Noted in Cognitive Processes and Association With Achievement Among Children With Leukemia.

Age-adjusted scores account for expected development, but the study cannot separate treatment effects from school absence, isolation, stress, or other factors. The children received protocol-based cancer treatment with different medications by protocol, so the study cannot attribute decline to one specific drug or component. Risk comparisons were limited because only 4 children were low risk and 2 were very high risk, so these groups were pooled with standard and high risk. Achievement correlations were based on smaller subgroups (43 children for visual matching and 29 for WRAML2), and missing data were assumed to be missing at random. The cognitive battery required English fluency, so results may not apply to children who needed an interpreter. The WRAML2 composite could mask opposite changes because Number Letter declined while Finger Windows did not show a negative slope. The authors note that practice effects or feeling better could affect retest performance, and the study did not test causal mechanisms for decline.

The paper is listed as supported by NIH extramural research funding. The supplied text does not report author conflicts of interest or whether the sponsor designed or wrote the study.

Do not conclude that cancer treatment caused the cognitive decline. The children received protocol-based treatment, not a single tested intervention, and the study observed change over time without showing a cause. The authors also state that decline does not suggest impairment.